Antibody Therapy Market Size, Growth Analysis 2023-2032

Antibody Therapy Market - By Type [Monoclonal Antibodies (mAbs) {Oncology, Autoimmune Disease, Infectious Disease}, Antibody-drug Conjugates (ADCs)], By End-use (Hospitals, Specialty Centers) – Global Forecast, 2023 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; workings

1.2.1&nbsp;&nbsp;&nbsp; Data collection

1.3&nbsp;&nbsp;&nbsp; Forecast calculations

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data sources

1.5.1&nbsp;&nbsp;&nbsp; Primary

1.5.2&nbsp;&nbsp;&nbsp; Secondary

1.5.2.1&nbsp;&nbsp;&nbsp; Paid sources

1.5.2.2&nbsp;&nbsp;&nbsp; Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Antibody therapy market 3600 synopsis, 2018 - 2032 (USD Million)

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Type trends

2.1.4&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;Antibody Therapy Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of chronic and infectious disease worldwide

3.2.1.2&nbsp;&nbsp;&nbsp; Growing R&amp;D activities

3.2.1.3&nbsp;&nbsp;&nbsp; High rate of adoption and approval in the U.S. and Europe

3.2.1.4&nbsp;&nbsp;&nbsp; Booming biologics industry

3.2.1.5&nbsp;&nbsp;&nbsp; Rising applications of antibody therapy

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of some monoclonal antibody therapeutics

3.2.2.2&nbsp;&nbsp;&nbsp; Complex manufacturing processes and logistical challenges

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By type

3.3.2&nbsp;&nbsp;&nbsp; By end-use

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Pipeline products

3.5.1&nbsp;&nbsp;&nbsp; Monoclonal antibodies

3.5.2&nbsp;&nbsp;&nbsp; Antibody drug conjugates

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players, 2022

4.4&nbsp;&nbsp;&nbsp; Company positioning matrix, 2022

4.5&nbsp;&nbsp;&nbsp; Strategy outlook matrix, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Antibody Therapy Market Size and Forecast, By Type, 2018-2032 (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by type

5.2&nbsp;&nbsp;&nbsp; Monoclonal antibodies (mAbs)

5.2.1&nbsp;&nbsp;&nbsp; Oncology

5.2.2&nbsp;&nbsp;&nbsp; Autoimmune diseases

5.2.3&nbsp;&nbsp;&nbsp; Infectious diseases

5.2.4&nbsp;&nbsp;&nbsp; Other monoclonal antibodies (mAbs)

5.3&nbsp;&nbsp;&nbsp; Antibody-drug conjugates (ADCs)

Chapter 6&nbsp;&nbsp;&nbsp;Antibody Therapy Market Size and Forecast, By End-Use, 2018-2032 (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

6.2&nbsp;&nbsp;&nbsp; Hospitals

6.3&nbsp;&nbsp;&nbsp; Specialty centers

6.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 7&nbsp;&nbsp;&nbsp;Antibody Therapy Market Size and Forecast, By Region, 2018-2032 (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by region

7.2&nbsp;&nbsp;&nbsp; North America

7.2.1&nbsp;&nbsp;&nbsp; U.S.

7.2.2&nbsp;&nbsp;&nbsp; Canada

7.3&nbsp;&nbsp;&nbsp; Europe

7.3.1&nbsp;&nbsp;&nbsp; Germany

7.3.2&nbsp;&nbsp;&nbsp; UK

7.3.3&nbsp;&nbsp;&nbsp; France

7.3.4&nbsp;&nbsp;&nbsp; Italy

7.3.5&nbsp;&nbsp;&nbsp; Spain

7.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

7.4&nbsp;&nbsp;&nbsp; Asia Pacific

7.4.1&nbsp;&nbsp;&nbsp; China

7.4.2&nbsp;&nbsp;&nbsp; Japan

7.4.3&nbsp;&nbsp;&nbsp; India

7.4.4&nbsp;&nbsp;&nbsp; Australia

7.4.5&nbsp;&nbsp;&nbsp; Singapore

7.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

7.5&nbsp;&nbsp;&nbsp; Latin America

7.5.1&nbsp;&nbsp;&nbsp; Brazil

7.5.2&nbsp;&nbsp;&nbsp; Mexico

7.5.3&nbsp;&nbsp;&nbsp; Argentina

7.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

7.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

7.6.1&nbsp;&nbsp;&nbsp; South Africa

7.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

7.6.3&nbsp;&nbsp;&nbsp; UAE

7.6.4&nbsp;&nbsp;&nbsp; Kuwait

7.6.5&nbsp;&nbsp;&nbsp; Egypt

7.6.6&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 8&nbsp;&nbsp;&nbsp;Company Profiles

8.1&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

8.2&nbsp;&nbsp;&nbsp; AbbVie, Inc.

8.3&nbsp;&nbsp;&nbsp; Amgen Inc.

8.4&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

8.5&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson Services, Inc.

8.6&nbsp;&nbsp;&nbsp; Seagen

8.7&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

8.8&nbsp;&nbsp;&nbsp; Regeneron Pharmaceuticals Inc.

8.9&nbsp;&nbsp;&nbsp; Novartis AG

8.10&nbsp;&nbsp;&nbsp; AstraZeneca

8.11&nbsp;&nbsp;&nbsp; Eli Lilly and Company

8.12&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc.

8.13&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Ltd.

&nbsp;

Antibody Therapy Market

Request Discount

Industries

Information

Link

Global Headquarters